About Ansun BioPharma
Ansun BioPharma is a Healthcare company based in San Diego (United States) founded in 2003. Anti-viral therapies for respiratory viruses are developed. Ansun BioPharma has raised $191.4 million across 9 funding rounds from investors including HHS, Sinopharm and Yuan Ming Capital. The company has 34 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Ansun BioPharma was founded in 2003 and is based in San Diego, United States. Focus is placed on the biopharmaceutical sector, where anti-viral therapies for respiratory viruses are developed. Lead candidates Fludase and Paradase incorporate DAS-181, a bifunctional fusion protein that combines sialidase with a polycationic sequence from human amphiregulin to target glycosaminoglycans. Operations center on advancing these therapies through research and development.
- Headquarters San Diego, United States
- Employees 34
- SectorsHealthcare
- Website ansunbiopharma.com
- Social LinkedIn X Facebook
- Total Equity Funding$191.4M (USD)
in 9 rounds
- Latest Funding Round$80M (USD), Series B
Oct 2019
- InvestorsHHS
& 14 more
- Employee Count34
Funding Insights of Ansun BioPharma
Ansun BioPharma has successfully raised a total of $191.4M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $80 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $191.4M
- Total Rounds 9
- Last Round Series B — $80M
- First Round $299,998
(Feb 2010)
- Investors Count 15
All 9 funding rounds of Ansun BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $80M | Series B | – | Oceanpine Capital, Korea Investment Partners | |
| May 2018 | $85M | Series A | – | Sinopharm, Lilly Asia Ventures | |
| Mar 2018 | $1.65M | Debt – Conventional | – | – | – |
| Dec 2015 | $4M | Series A | – | – | – |
| May 2014 | $7.5M | Series A | – | – | – |
| May 2013 | $5M | Series A | – | – | – |
| Nov 2011 | $9.9M | Series A | – | – | – |
| Mar 2010 | $299,998 | Grant | – | – | |
| Feb 2010 | $299,998 | Grant | – | – |
15 investors in total: 15 institutional.
Investors in Ansun BioPharma
Ansun BioPharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Sinopharm and Yuan Ming Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm focused on medicine based companies | yuanmingcap.cn | Haidian, China | ||
LYFE Capital is recognized as a premier healthcare investment platform. | lyfecapital.com | Menlo Park, USA | ||
Multiple sectors are invested in by this venture capital firm. | matrixpartners.com.cn | Chaoyang, China | ||
Tech startups are invested in by this venture capital firm. | kipvc.cn | Singapore, Singapore | ||
Venture capital funding is provided across multiple sectors. | gbahomeland.com | Hong Kong, China | ||
A fund focused on healthcare industry investments is managed. | 2015 | 3ebiovc.cn | China | |
| jiachengcap.com | ||||
Tech & Life Science focused early & growth stage VC firm investing in the US & China | 3ebiovc.com | Beijing, China | ||
Investment in healthcare sector is facilitated by the fund. | oceanpinecap.com | |||
| vi-ventures.com |
Investor details for Ansun BioPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ansun BioPharma
19 people are tracked at Ansun BioPharma (7 in leadership, 8 in board & advisors, 4 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Nancy Chang | CEO & Chairperson | Leadership |
Yining Zhao | President & COO | Leadership |
Stanley Lewis | CMO | Leadership |
Winnie Chan | Sr. Director, R&D | Leadership |
George Y. Wang | CTO | Leadership |
Lisa Li | Associate Director Clinical Operations | Leadership |
Courtney Burke | Associate Director | Leadership |
Michael Chao | Director | Board & advisors |
Aimin Wu | Director | Board & advisors |
Donald Payne | Director | Board & advisors |
Dave Chenn | Director | Board & advisors |
Yi Shi | Director | Board & advisors |
Michael Chang | Director | Board & advisors |
Allen Chao | Director | Board & advisors |
Karen Liu | Director | Board & advisors |
JianCong Liu | SVP of Clinical Development | Team |
Lana O. | Manager of Regulatory and Document Control | Team |
Trevor Vernon Gale, Ph.D. | Research Scientist | Team |
Stephen Hawley | Senior Principal Scientist | Team |
Complete people profiles for Ansun BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ansun BioPharma
3 dated milestones of Ansun BioPharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Ansun BioPharma is founded.
- Funding First funding round of $300K.
- Funding Latest funding round, Series B, of $80.0M.
Competitors of Ansun BioPharma
Ansun BioPharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Ansun BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ansun BioPharma
Websites that share an audience with Ansun BioPharma (ansunbiopharma.com).
Websites whose visitors overlap most with Ansun BioPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alfascientific.com | 100% | #8,547,751 | View details | ||
| carihealth.com | 99% | View details | |||
| restech.com | 97% | View details | |||
ithrivebeauty.com | ithrivebeauty.com | 96% | #6,774,498 | – | |
kadencehealthcare.com | kadencehealthcare.com | 96% | #7,313,283 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Ansun BioPharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Ansun BioPharma (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ansun Biopharma
Complete news archive for Ansun BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ansun BioPharma
Ansun BioPharma was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Ansun BioPharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ansun BioPharma is a funded company, having raised a total of $191.4M across 9 funding rounds to date. The company's 1st funding round was a Grant of $300K, raised on Feb 2010.
Ansun BioPharma has 34 employees.
Ansun BioPharma was founded in 2003 and is based in San Diego, United States. Focus is placed on the biopharmaceutical sector, where anti-viral therapies for respiratory viruses are developed. Lead candidates Fludase and Paradase incorporate DAS-181, a bifunctional fusion protein that combines sialidase with a polycationic sequence from human amphiregulin to target glycosaminoglycans. Operations center on advancing these therapies through research and development.
Ansun BioPharma's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Ansun BioPharma has 15 investors. Key investors include HHS, Sinopharm, Yuan Ming Capital, Lilly Asia Ventures, and LYFE Capital.